[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pre-eclampsia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pre-eclampsia":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,47,66,92,126,157,181,208,238,264,291,331,352,381,410,432,451,475,504,529,559,592,615,639,661],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100389856","phase-3-chronic-hypertension-and-acetyl-salicylic-acid-in-pregnancy-100389856",false,"NCT04356326","Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy","Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy, a Multicenter Prospective Randomized Double-blind Placebo-controlled Trial.","CHASAP","Inclusion Criteria:\n\n* Pregnant patient between 10 and 19 weeks of gestation + 6 days\n* Chronic hypertension, whether treated or not, know before pregnancy or diagnosed before randomization\n* Singleton pregnancy\n* Signed the written informed consent\n* Affiliation to social security\n\nExclusion Criteria:\n\n* ---Medical history requiring anticoagulation (antiphospholipid syndrome, deep vein thromboembolic disease, pulmonary embolism, atherothrombosis, patient with mechanical heart valves),\n* Patient receiving aspirin for another indication outside pregnancy,\n* Patient with significant proteinuria (\\> 300mg\u002F24 hours or a proteinuria\u002Fcreatininuria ratio ≥ 30mg\u002Fmmol),\n* Active bleeding,\n* History of severe PE with delivery \\\u003C 34 weeks of gestation,\n* Hypersensitivity to salicylates such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs),\n* Platelet count lower than 100,000 cells\u002Fmicroliter (dosage less than 6 months old),\n* Hemostasis disorders, including hemophilia (with thrombocytopenia)\n* Any constitutional or acquired hemorrhagic disease, (including digestive hemorrhages, history of hemorrhagic stroke and thrombocytopenia\n* Human immunodeficiency virus, or hepatitis B virus, or hepatitis C virus positive serum,\n* Patient included in another interventional study which could interfere with the results of the study,\n* Age \\\u003C18 years old,\n* Women under the protection of justice,\n* Patients with psychiatric follow-up, poor understanding of French or cognitive problems,\n* Duodenal ulcer,\n* Severe renal impairment,\n* Severe hepatic insufficiency,\n* Severe cardiac impairment,\n* Gout,\n* Patients with known glucose-6-phosphate dehydrogenase deficiency,","FEMALE","18 Years",{"count":21,"type":22},500,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","A randomized clinical trial to assess the efficiency of acetylsalicylic acid (aspirin) 150 mg\u002Fday started before 20 weeks of gestation in the prevention on maternal and fœtal complications in pregnant women with chronic hypertension.",[28,29,30,31,32,33],"Chronic Hypertension Complicating Pregnancy","Pre-Eclampsia","Intrauterine Growth Restriction","Aspirin","Perinatal Death","Placental Abruption","RECRUITING","2026-06-11",{"date":37,"type":38},"2026-06-12","ACTUAL",{"date":40,"type":38},"2021-02-15",{"date":42,"type":22},"2030-02",{"name":44,"class":45},"Centre Hospitalier Intercommunal Creteil","OTHER",20,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":59,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100333814","study-of-the-physiology-of-pre-eclampsia-and-vascular-iugr-with-constitution-of-a-biological-collection-100333814","NCT03626233","Study of the Physiology of Pre-eclampsia and Vascular IUGR With Constitution of a Biological Collection","Study of the Physiology of Pre-eclampsia and Vascular Intrauterine Growth Restriction With Constitution of a Biological Collection","CPVP","Inclusion Criteria:\n\n* pregnant women\n* With or without vascular pathology\n\nExclusion Criteria:\n\n* refusal to participate\n* multiple pregnancy\n* major fetal malformation diagnosed during pregnancy follow-up",{"count":21,"type":22},"OBSERVATIONAL","Preeclampsia and intrauterine growth retardation (IUGR) are serious and frequent pathologies, specific to pregnancy. They represent 70 000 new cases a year, or 9% of pregnancies and cause 50,000 premature births per year in France. The consequences in terms of morbidity and perinatal morbidity and the medical and economic costs make it an issue public health. Pre-eclampsia associates maternal hypertension with dysfunction kidney. There is no cure for pre-eclampsia or IUGR vascular during pregnancy. These pathologies invariably evolve towards a maternal and \u002F or fetal aggravation sometimes very fast. Primary prevention and secondary education and screening for these pathologies are still insufficient. A better understanding of the pathophysiology of these placental vascular pathologies is necessary for the development of supported medical, obstetric and pediatric that will improve the state of health maternal and neonatal",[29],{"date":37,"type":38},{"date":61,"type":38},"2018-08-06",{"date":63,"type":22},"2028-08",{"name":44,"class":45},1,{"id":67,"slug":68,"hasResults":12,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":65},"100584757","virtual-reality-based-and-face-to-face-relaxation-programs-in-pregnant-women-with-preeclampsia-100584757","NCT06893510","Virtual Reality-Based and Face-to-Face Relaxation Programs in Pregnant Women With Preeclampsia","The Effect of Virtual Reality-Based and Face-to-Face Relaxation Programs on Maternal and Fetal Outcomes in Pregnant Women With Preeclampsia","Inclusion Criteria:\n\n* Hospitalized with a diagnosis of preeclampsia.\n* Gestational age ≥26 weeks.\n* 18 years or older.\n* Singleton and viable pregnancy.\n* Willing to participate in the study voluntarily.\n\nExclusion Criteria:\n\n* Multiple pregnancy.\n* Pregnancy achieved through assisted reproductive technologies.\n* Hearing or vision impairment in the pregnant individual.\n* Fetal distress requiring emergency intervention.\n* HELLP Syndrome or Eclampsia.\n* History of vertigo.\n\nWithdrawal Criteria:\n\n* Cases where live birth does not occur.\n* Participants who voluntarily withdraw from the study.\n* Participants whose general health condition deteriorates during the intervention.\n* Participants experiencing side effects from virtual reality headset use (e.g., dizziness, nausea, headache).\n* Participants who do not practice progressive muscle relaxation at least once a week after the intervention.",{"count":74,"type":22},96,[76],"NA","Preeclampsia, affecting 2-8% of pregnancies globally, is a leading hypertensive disorder in pregnancy. It is clinically characterized by elevated blood pressure (≥140\u002F90 mmHg) after the 20th gestational week, often accompanied by proteinuria and systemic complications such as thrombocytopenia, liver dysfunction, and cerebral symptoms. This condition poses significant risks for both maternal and fetal health, increasing the likelihood of organ damage, preterm birth, and long-term cardiovascular and neurodevelopmental complications. Non-pharmacological interventions, including relaxation techniques, have been explored for symptom management. Progressive muscle relaxation (PMR) has shown efficacy in reducing stress, anxiety, and blood pressure. Recently, virtual reality (VR)-based relaxation techniques have gained attention for enhancing stress relief and improving health outcomes. This study aims to compare the effects of VR-based PMR with in-person PMR on maternal and fetal outcomes in preeclamptic pregnancies.",[29,79,80,81,82],"Maternal Health","Relaxation","Virtual Reality","Fetal Monitoring","2026-06-07",{"date":85,"type":38},"2026-06-10",{"date":87,"type":38},"2025-09-08",{"date":89,"type":22},"2026-09-01",{"name":91,"class":45},"Istanbul University - Cerrahpasa",{"id":93,"slug":94,"hasResults":12,"nctId":95,"briefTitle":96,"officialTitle":96,"acronym":97,"eligibilityCriteria":98,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":102,"briefSummary":104,"conditions":105,"keywords":116,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":65},"100537733","phase-4-treatment-with-aspirin-after-preeclampsia-tap-trial-100537733","NCT06281665","Treatment With Aspirin After Preeclampsia: TAP Trial","TAP","Inclusion Criteria:\n\n* Postpartum individuals ≥18 years old\n* Preeclampsia diagnosis\n\nExclusion Criteria:\n\n* Fetal anomaly\n* Multiple gestation\n* Pre-pregnancy hypertension\n* Allergy or contraindication to low-dose aspirin\n* Pre-pregnancy diabetes","55 Years",{"count":101,"type":22},60,[103],"PHASE4","The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and\u002For microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.",[106,29,107,108,109,110,111,112,113,114,115],"Hypertensive Disorder of Pregnancy","Hypertension","Eclampsia","Gestational Hypertension","Cardiovascular Diseases","Toxemia","Pregnancy Complications","Vascular Diseases","Hypertension, Pregnancy Induced","Hypertension;Pre-Eclamptic",[107],"2026-06-03",{"date":119,"type":38},"2026-06-04",{"date":121,"type":38},"2024-05-29",{"date":123,"type":22},"2027-09-01",{"name":125,"class":45},"Malamo Countouris",{"id":127,"slug":128,"hasResults":12,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":135,"minAge":19,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":23,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":65},"100637673","clinical-validation-of-the-blood-pressure-measuring-device-withings-bpm-pro-2-in-pregnancy-and-pre-eclampsia-100637673","NCT07595016","Clinical Validation of the Blood Pressure Measuring Device Withings BPM Pro 2 in Pregnancy and Pre-Eclampsia","Clinical Validation Of The Brachial Blood Pressure Measuring Device Withings BPM Pro 2 According To \"The Universal Protocol For The Validation Of Blood Pressure Measuring Devices By The Association For The Advancement Of Medical Instrumentation \u002F European Society Of Hypertension \u002F International Organization For Standardization (AAMI\u002FESH\u002FISO) (And Its Amendment 1 (2020) And 2 (2024))\" In Pregnancy And Pre-Eclampsia","WIHYP-PW","Inclusion Criteria:\n\n* Patient older than 18 years;\n* Known pregnancy, in second or third trimester of pregnancy ( \\> 3 months);\n* Patient normotensive, hypertensive or in preeclampsia;\n* Patient who signed the informed consent form;\n* Patient followed-up at site (in-patient or out-patient);\n* Patient with arm circumference between 22 cm and 42 cm.\n\nExclusion Criteria:\n\n* Patient unable to give a consent or understand properly protocol information;\n* Patient suffering from arrhythmia;\n* Patient with poor quality of Korotkov sounds;\n* Patient for whom K5 sounds are absent;\n* Patient wearing an implantable electric medical device (pacemaker,…);\n* Patient with both upper arms suffering from open wound and\u002For damaged skin.",true,"ALL",{"count":137,"type":22},45,[76],"The aim of the study is to assess the accuracy of the automatic oscillometric BP measuring device at the brachial level, the WITHINGS BPM Pro 2, in pregnancy and pre-eclampsia",[107,141],"Pre-eclampsia",[143,144,145,146,147],"hypertension","blood pressure monitor","pregnancy","pre-eclampsia","validation","2026-06-01",{"date":117,"type":38},{"date":151,"type":38},"2026-05-11",{"date":153,"type":22},"2026-09-30",{"name":155,"class":156},"Withings","INDUSTRY",{"id":158,"slug":159,"hasResults":12,"nctId":160,"briefTitle":161,"officialTitle":162,"acronym":163,"eligibilityCriteria":164,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":23,"phases":167,"briefSummary":168,"conditions":169,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":180},"100487333","phase-3-aspirin-for-the-prevention-of-preeclampsia-and-pregnancy-outcomes-after-assisted-reproductive-technology-100487333","NCT05625724","Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology","Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes in Nulliparous Women After Assisted Reproductive Technology. APPART","APPART","Inclusion Criteria:\n\n* Nulliparous women aged 18 years or more\n* Pregnancy following ART, including in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), oocyte donation or intrauterine insemination with sperm donor\n* Singleton pregnancy\n* Evolutive pregnancy between 9 and 14 weeks of gestation\n* Women affiliated to a French Social Security Insurance or equivalent social protection\n* Written informed consent\n\nExclusion Criteria:\n\n* Major fetal abnormality\n* Regular treatment with aspirin (including antiphospholipid syndrome)\n* Aspirin contraindications (allergy, von Willebrand disease, peptic ulceration, hemophilia)\n* Women protected by law.\n* Women included in another interventional study.",{"count":166,"type":22},1164,[25],"This study seeks to validate the hypothesis that nulliparous pregnant women after Assisted Reproductive Technology (ART) are at high risk of preeclampsia and perinatal complications and represent a subgroup for which aspirin prophylaxis during pregnancy may be effective in the prevention of preterm preeclampsia and other perinatal adverse outcomes.",[170,29],"ART","2026-05-04",{"date":173,"type":38},"2026-05-07",{"date":175,"type":38},"2023-08-02",{"date":177,"type":22},"2029-05",{"name":179,"class":45},"University Hospital, Toulouse",21,{"id":182,"slug":183,"hasResults":12,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":65},"100576025","autophagyapoptosis-balance-in-placental-vascular-pathologies-100576025","NCT06779916","Autophagy\u002FApoptosis Balance in Placental Vascular Pathologies","Study of the Autophagy\u002FApoptosis Balance in Placental Vascular Pathologies","GROSSAUTOP-2","Inclusion Criteria:\n\n* Pregnant women developing a placental vascular complication (preeclampsia and\u002For intrauterine growth retardation), hospitalized and delivering at Nimes University Hospital.\n* Pregnant woman with free and informed consent.\n* Pregnant woman affiliated with and\u002For benefiting from a health insurance scheme.\n\nExclusion criteria:\n\n* Multiple pregnancy.\n* Presence of hypertension and\u002For proteinuria prior to pregnancy.\n* Participant in an interventional drug study.\n* Persons in a period of exclusion determined by another study.\n* Persons under court protection, guardianship or curatorship.\n* Persons unable to give consent.\n* Persons for whom it is impossible to give informed information.",{"count":190,"type":22},50,"Pregnancy increases the risk of thrombosis. Placenta-mediated diseases are a risk factor for cardiovascular pathologies and can lead to maternal-fetal morbidity and mortality. It is essential to understand the cellular and molecular mechanisms of dysfunctions at the vascular-placental interface so that systemic vascular risk can be characterized and, ultimately, screened for, on the basis of new markers (targeted preventive management).\n\nDeregulated autophagy could be the starting point for cell death by apoptosis or necrosis leading to complications.\n\nThe pathophysiological mechanisms involved in trophoblast apoptosis are incompletely described. This project follows on from the GrossAuTop-1 study, which investigated the intra- and inter-individual variability of autophagy and apoptosis activities in women during pregnancy. The aim of this project is to study autophagy and apoptosis activities specifically in women developing a placental vascular complication during pregnancy.",[112,29,193],"Growth Retardation, Intrauterine",[195,196,197,198,145],"trophoblasts","autophagy","apoptosis","placenta","2026-04-30",{"date":201,"type":38},"2026-05-06",{"date":203,"type":38},"2025-05-02",{"date":205,"type":22},"2029-05-01",{"name":207,"class":45},"Centre Hospitalier Universitaire de Nīmes",{"id":209,"slug":210,"hasResults":12,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":134,"sex":18,"minAge":19,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":219,"briefSummary":220,"conditions":221,"keywords":224,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":237},"100472616","clinical-antenatal-randomised-study-to-characterise-key-roles-of-tetrahydrofolate-in-hypertensive-pregnancies-100472616","NCT05434195","Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies","Clinical Antenatal Randomised Study to CharactErise Key Roles of TetrahydroFOLate in HyperTensive Pregnancies (CAREFOL-HT)","CAREFOL-HT","Inclusion Criteria (Preeclampsia individuals):\n\n* Diagnosed with preeclampsia, as defined in Section 8.1, at \\\u003C34 weeks' gestation within the last 48 hours and with no delivery planned within the next week\n* Receiving antenatal care in the John Radcliffe Hospital\n* Participant is willing and able to give informed consent for participation in the study\n* Age \\>18 and ≤45 years\n\nExclusion Criteria (Preeclampsia individuals):\n\nThe participant may not enter the study if ANY of the following apply:\n\nMaternal\n\n* History of cardiac impairments including uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure or valve disease\n* History of preexisting chronic renal disease\n* Contraindication to taking folate related supplements\n* Folate supplementation in excess of 400mcg in the third trimester\n* Low vitamin B12 levels (\\\u003C148 pmol\u002FL)\n* Intake of either proton pump inhibitors or anti-epileptic drugs\n* Organ dysfunction Fetal\n* Any known trisomy\n* Fetus with congenital heart defect\n* Fetus at a high risk of heart disease\n* Known infection of fetus\n* Known severe anaemia\n\nInclusion Criteria (Normotensive individuals):\n\n* Participant is willing and able to give informed consent for participation in the study\n* Age \\>18 and ≤45 years\n* Normotensive, blood pressures \\\u003C140\u002F90 throughout antenatal period\n* Less than 2 moderate risk factors for hypertensive disease in pregnancy according to the NICE guideline for management of hypertension in pregnancy\n* SFlt\u002FPIGF ratio \\\u003C35\n\nExclusion Criteria (Normotensive individuals):\n\nThe participant may not enter the study if ANY of the following apply:\n\nMaternal\n\n* Diagnosis of hypertensive disorder of pregnancy\n* Use of beta blockers such as atenolol or equivalent\n* History of cardiac impairments including uncontrolled arrhythmia, unstable angina, decompensated congestive heart failure or valve disease\n* History of preexisting chronic renal disease Fetal\n* Any known trisomy\n* Fetus with congenital heart defect\n* Fetus at a high risk of heart disease\n* Known infection of fetus\n* Known severe anaemia","45 Years",{"count":218,"type":22},128,[76],"Study background\n\nHigh blood pressure during pregnancy is a worldwide health problem that can be dangerous to mothers and commonly causes premature birth and small babies. There is also growing evidence that mothers who suffer from high blood pressure in pregnancy, and their babies, have a higher risk of high blood pressure and cardiovascular disease later in life. Previous studies have revealed detrimental changes in the structure and function of the heart and blood vessels of mothers, and their babies, who experience this common complication. These changes may explain their increased risk of later disease. The investigators have also learned through previous studies that tetrahydrobiopterin (BH4), a molecule that has a role in blood vessel health, plays an important role in stabilising blood vessel function. Lower levels of BH4 are evident in both the placenta and the umbilical cord from mothers with high blood pressure. We, therefore, want to investigate how closely BH4 levels are related to clinical features of pre-eclampsia and whether altering levels of BH4, using a nutritional supplement, improves features of the disease such as blood vessel function. To do this, the investigators need to compare the levels of BH4 between mothers with pre-eclampsia, those taking the supplement and those without pre-eclampsia. The investigators also compare how the heart and blood vessels look and function in these groups using ultrasound methods, including echocardiography and fetal sonography.\n\nStudy objectives\n\nCAREFOL-HT will assess how levels of BH4 differ in pregnant women with high blood pressure and if this is reflected in functional changes in the heart and blood vessels of these women. The investigators will also determine whether changing levels of BH4, using a tetrahydrofolate supplement (5-MTHF), changes blood vessel function.",[29,222,223],"Pregnancy Induced Hypertension","Pregnancy Related",[225,226,29,227],"5-methyltetrahydrofolate","Tetrahydrobiopterin","Antenatal study","2026-04-28",{"date":230,"type":38},"2026-04-29",{"date":232,"type":38},"2021-06-01",{"date":234,"type":22},"2026-10",{"name":236,"class":45},"University of Oxford",2,{"id":239,"slug":240,"hasResults":12,"nctId":241,"briefTitle":242,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":134,"sex":18,"minAge":245,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":248,"conditions":249,"keywords":250,"overallStatus":255,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":65},"100598481","oxford-luteal-dysfunction-and-placental-insufficiency-study-100598481","NCT07072052","Oxford Luteal Dysfunction and Placental Insufficiency Study","OxLuPIn","Inclusion Criteria:\n\n* Participant is willing and able to give written informed consent for participation in the study.\n* Female, aged 16 years or above. As in vitro fertilisation is not undertaken in women younger than 18 years, those with pregnancies resulting from natural cycle frozen embryo transfer will be aged 18 years or above.\n* Pregnancy \\\u003C8 completed weeks of gestation (i.e., up to 7 weeks and 6 days' gestation).\n* Conception through any of the following means: unassisted (\"natural\"), ovulation induction (with clomifene citrate, letrozole or gonadotropin injections, including trigger injection), intrauterine insemination (with or without ovulation induction, including trigger injection), or natural cycle frozen embryo transfer.\n* Intrauterine viable pregnancy confirmed on research ultrasound scan.\n* Intention to deliver at Oxford University Hospitals.\n\nExclusion Criteria:\n\n* Unable to read, or to understand written or spoken English.\n* Vaginal bleeding at first visit.\n* Miscarriage at first visit, defined as fetal crown-rump length of 7 mm or longer with no visible heartbeat, OR gestational sac with a mean of 25 mm or greater in diameter with no visible fetal pole on ultrasonography.\n* Evidence of ectopic pregnancy at first visit.\n* Multiple pregnancy.\n* Uterine pathology (e.g., uterine polyp, fibroid, septate uterus, uterus didelphys, bicornuate uterus, unicornuate uterus).\n* Fresh in vitro fertilisation.\n* Donor oocyte in vitro fertilisation.\n* Frozen embryo transfer using hormone replacement therapy for endometrial preparation.\n* Participation in any concurrent trials of medicinal products in pregnancy.","16 Years",{"count":247,"type":22},360,"High blood pressure (BP) affects approximately 1 in 10 pregnancies. About half of women with high blood pressure in pregnancy develop a serious complication called preeclampsia, which kills over 70,000 women and 500,000 babies every year worldwide. Despite its devastating impact, scientists know little about preeclampsia prevention or treatment. Research has shown that preeclampsia results mainly from an abnormal attachment of the placenta to the lining of the womb. In the first 8 weeks of pregnancy, placental attachment depends on the release of hormones (for example, progesterone) by a gland in the ovary called the corpus luteum. Low blood levels of progesterone in early pregnancy are associated with a reduced chance of having a live baby and higher risk of miscarriage. Giving progesterone to women at risk of miscarriage in early pregnancy reduces their chance of developing preeclampsia by nearly 40%. These results highlight the crucial role of the corpus luteum in normal pregnancy, but there is a need for high-quality studies to identify women whose corpus luteum may be defective. Giving these women medicines to treat corpus luteal defects may lead to normal attachment of the placenta, reducing the risk of pregnancy complications such as preeclampsia. The investigators propose a study that will investigate whether ultrasound features of the corpus luteum and blood and urine levels of corpus luteal hormones may predict preeclampsia.",[141],[251,146,252,253,254],"corpus luteum","early pregnancy","prognostic marker","risk stratification","NOT_YET_RECRUITING","2026-04-20",{"date":258,"type":38},"2026-04-23",{"date":260,"type":22},"2026-05",{"date":262,"type":22},"2027-01",{"name":236,"class":45},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":23,"phases":274,"briefSummary":275,"conditions":276,"keywords":278,"overallStatus":255,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":237},"100545889","acute-beetroot-juice-supplementation-in-pre-eclampsia-pregnancies-100545889","NCT06387784","Acute Beetroot Juice Supplementation in Pre-eclampsia Pregnancies","Acute Effect of Beetroot Juice Supplementation in Pregnant Women With Pre-eclampsia: a Single-Blind Randomized Placebo-Controlled Trial","BEET_PE","1. Pre-eclampsia pregnat women\n\n   Inclusion Criteria:\n   * Pregnant women at or beyond the 20th week of gestation.\n   * Hospitalized at Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto.\n   * Diagnosed with early-onset pre-eclampsia confirmed by a medical professional.\n   * Capacity to provide written informed consent for study participation.\n\n   Exclusion Criteria:\n   * Multiple pregnancies.\n   * Uncontrolled arterial hypertension (Systolic Blood Pressure \\> 160 mmHg or Diastolic Blood Pressure \\> 100 mmHg).\n   * Pregnant women with a body mass index \\> 40 kg\u002Fm²\n   * Severe gestational complications.\n   * History of food allergy with hypersensitivity to beetroot.\n   * Smokers.\n   * Chronic alcohol consumption.\n   * Medications such as non-steroidal anti-inflammatory drugs, nasal decongestants, users of proton pump inhibitors and H2 receptor antagonists or any other medication that interferes with stomach pH.\n   * Diagnosis of renal or hepatic disease affecting nitrate metabolism.\n   * Cardiac conditions such as moderate to severe congestive heart failure and coronary artery disease.\n   * Pre-existing type 1 or type 2 diabetes.\n2. Healthy Pregnant Women\n\nInclusion Criteria:\n\n* Healthy pregnant women at or beyond the 20th week of gestation.\n* Absence of pre-eclampsia diagnosis or other obstetric complications.\n* Willingness and ability to remain admitted at the Clinical Research Unit for the - period required by the study.\n* Capacity to provide written informed consent for study participation.\n\nExclusion Criteria:\n\n\\- The same exclusion criteria from Pre-eclampsia group apply.","40 Years",{"count":101,"type":22},[76],"Pre-eclampsia is a serious condition that typically affects pregnant women after the 20th week of pregnancy, characterized by high blood pressure and damage to organs such as the kidneys and liver. Currently, treatment options are limited, which has prompted researchers to explore alternative approaches. One such promising alternative is dietary nitrate found in vegetables like beetroot, as nitrate can be converted into nitric oxide in the body, which helps lower blood pressure. This study aims to determine the acute effects of nitrate-rich beetroot juice on blood pressure, several blood and salivary markers in pregnant women with pre-eclampsia and healthy pregnant. Furthermore, the study will assess fetal blood flow using Doppler ultrasound. We want to understand the kinetics of nitrate and nitric oxide metabolites and assess the temporal dependency of the hypotensive response. Through this investigation, we seek evidence of nitrate-enriched beetroot juice as an adjunct therapy in managing pre-eclampsia.",[29,277],"Pregnacy",[141,279,280,281],"Pregnancy","Beetroot Juice","Nitric Oxide","2026-04-15",{"date":284,"type":38},"2026-04-21",{"date":286,"type":22},"2026-05-18",{"date":288,"type":22},"2028-07",{"name":290,"class":45},"University of Sao Paulo",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":301,"conditions":302,"keywords":315,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":330},"100613200","prior-study-pre-eclampsia-risk-in-oocyte-recipients-100613200","NCT07263490","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients)","PRIOR Study (Pre-eclampsia Risk In Oocyte Recipients) - Investigating Matching, Biomarkers and Outcomes.","PRIOR","Inclusion Criteria:\n\n* Age \\> 18 years\n* BMI \\\u003C 35 kg\u002Fm2\n* Normal wet smear within the past three years\n* Both nulli- and multiparous\n* Singletons and multiple gestations\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* BMI \\> 35 kg\u002Fm2\n* HIV\u002F hepatitis\n* Essential hypertension\n* Chronic kidney disease\n* Undiagnosed vaginal bleeding\n* Uterine malformations\n* Persisting ovarian cysts\n* Tumors in hypothalamus, pituitary, thyroid, or adrenal glands.\n* Previous breast cancer\n* Known BRCA 1 or 2 gene\n* Unregulated thyroid disease\n* Cardiovascular disease\n* Breast feeding\n* Present or previous chemotherapy\u002Fradiation therapy\n* Present or previous malignant disease\n* Smoking\n* Alcohol\u002Fdrug abuse",{"count":300,"type":22},462,"The aim of this prospective observational cohort study is to investigate the pathophysiological mechanisms behind and risk of pre-eclampsia in women pregnant after fertility treatment with oocyte donation. The participants are included in of of two cohorts. One includes women pregnant after oocyte donation whereas the other includes women pregnant after IVF treatment with autologous oocytes.\n\nParticipants will be followed throughout pregnancy with blood samples, blood pressure, clinical controls and ultrasound examinations. Clinical outcomes will be registered post-partum.",[141,303,304,305,306,307,170,308,309,33,310,311,312,313,314],"Oocyte Donation","Pre-Eclampsia; Complicating Pregnancy","Pre-Eclampsia; Mild","Pre-Eclampsia, Severe","Pre-eclampsia or Eclampsia With Pre-existing Hypertension","Neonatal Morbidity","Neonatal Mortality","Gestational Diabetes","Preterm Labor","Post-partum Hemorrhage (PPH)","Intrauterine Growth Restriction (IUGR)","Hypertensive Disorders of Pregnancy",[141,316,170,317,318,319,320],"Preeclampsia","Gestational hypertension","Oocyte donation","Egg donation","Gamete donation","2026-04-07",{"date":323,"type":38},"2026-04-13",{"date":325,"type":38},"2024-10-21",{"date":327,"type":22},"2028-06-01",{"name":329,"class":45},"Copenhagen University Hospital, Hvidovre",6,{"id":332,"slug":333,"hasResults":12,"nctId":334,"briefTitle":335,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":134,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":338,"conditions":339,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":65},"100629105","placental-biology-in-health-and-disease-100629105","NCT07470320","Placental Biology in Health and Disease","Inclusion Criteria:\n\n* Female, aged 18 years or above\n* Willing and able to give informed consent for participation in the study\n* Able to read and understand written and spoken English to comprehend study materials and give informed consent\n* Non-pregnant women in good general health OR pregnant women who fall into one of the following:\n\n  * Healthy pregnancy\n  * Pre-eclampsia (PET) - defined by clinical diagnostic criteria, including hypertension and proteinuria\n  * Gestational diabetes mellitus (GDM) - diagnosed by standard glucose tolerance tests during pregnancy\n  * Fetal growth restriction (FGR) - diagnosed based on fetal weight or Doppler abnormalities\n  * Predisposed to PET - high-risk factors for PET such as maternal type 1 or type 2 diabetes, autoimmune diseases or multiple pregnancies\n\nExclusion Criteria:\n\n* Non-pregnant participants with active health conditions that could confound study outcomes\n* Pregnant participants with conditions unrelated to PET, GDM or FGR that could influence EV profiles e.g. active infections or malignancies",{"count":247,"type":22},"Pre-eclampsia (PET) is a condition characterised by high blood pressure and damage to other organs, and is a leading cause of maternal and fetal complications such as fetal growth restriction (FGR). Gestational diabetes mellitus (GDM) involves abnormal blood sugar levels during pregnancy and can have both short and long-term impacts on the health of the mother and child. Both conditions are linked to placental dysfunction but the precise mechanisms behind these links remain unclear.\n\nA major focus of this study is on extracellular vesicles (EVs) which are tiny, bubble-like particles released by the placenta into the mother's and baby's bloodstreams. These EVs act as messengers, carrying proteins, lipids and genetic material that can influence how cells function, even in parts of the body far from the placenta. Notably, the number and content of these EVs change in conditions like PET and GDM, suggesting they may play a role in the development of these complications.\n\nThis single-site, observational, laboratory study aims to investigate how these EVs contribute to maternal health and disease. To enable analysis across different physiological and pathological conditions pregnant participants with healthy pregnancies, pregnancies predisposed to PET and pregnancies complicated by GDM, FGR and PET will be recruited alongside healthy non-pregnant controls. Recruitment will be from the Oxford University Hospitals NHS Foundation Trust and the Nuffield Department of Women's and Reproductive Health, University of Oxford (who fund the research). Demographic and clinical data will be collected as well as blood, urine, breath, placenta, umbilical cord, umbilical cord blood, amniotic fluid and\u002For uterine vein blood samples.\n\nThrough examining EV content and function, it is hoped a better understanding of their role in pregnancy complications will be gained, including their potential as non-invasive biomarkers for early detection and targeted treatments, improving outcomes for mothers and babies worldwide.",[141,340,341,342,343,279],"Gestational Diabetes Mellitus (GDM)","Fetal Growth Restriction (FGR)","Pregnancy Induced Hypertension (PIH)","Placenta","2026-03-09",{"date":346,"type":38},"2026-03-13",{"date":348,"type":38},"2025-12-16",{"date":350,"type":22},"2030-05-31",{"name":236,"class":45},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":23,"phases":361,"briefSummary":362,"conditions":363,"keywords":366,"overallStatus":255,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":377,"leadSponsor":379,"locationsCount":65},"100628235","usability-evaluation-of-gen-ai-based-nutrition-chatbot-for-pregnant-women-100628235","NCT07458997","Usability Evaluation of Gen AI-based Nutrition Chatbot for Pregnant Women","Usability Evaluation of Gen AI-based Nutrition Chatbot for Pregnant Women: A Pilot Quasi-experimental Study","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* Able to provide informed consent in the study language\n* Own a smartphone with internet access and the WeChat application\n\nExclusion Criteria:\n\n* Current enrollment in other nutrition intervention studies\n* Severe mental health conditions that may impair technology use or ability to provide informed consent",{"count":360,"type":22},100,[76],"Background: Pregnancy imposes significant physical demands, with complications like gestational diabetes (GDM) and pre-eclampsia posing serious risks. Nutrition is crucial for mitigation, but accessing reliable guidance remains challenging. This study evaluates the feasibility of an AI chatbot providing nutritional guidance for managing these conditions.\n\nMethods: In a quasi-experimental design, 100 pregnant women will self-select into either the intervention group (n=50, using an AI chatbot) or control group (n=50, receiving standard care). The primary outcome is usability measured by the System Usability Scale (SUS) at 12 weeks, with an expected mean difference of ≥13 points. Secondary outcomes include technology acceptance (Technology Acceptance Model), user engagement, information accuracy, and changes in dietary knowledge\u002Fbehaviors. Quantitative data will be analyzed using intention-to-treat and t-tests. Semi-structured interviews with 20 participants will explore user experiences through thematic analysis.\n\nExpected Results: The AI chatbot is anticipated to demonstrate superior usability and high user acceptance (TAM \\>5.0\u002F7), with improvements in dietary knowledge and behavior. Qualitative findings will provide insights into benefits, barriers, and engagement factors.\n\nConclusion: This study will establish an evidence base on AI chatbot feasibility and acceptance for prenatal nutrition, informing tool optimization and future large-scale trials.",[364,141,365],"Diabetes, Gestational","AI Chatbot for Prenatal Nutrition Guidance",[367,368,369,146,370,371,372,373],"AI chatbot","prenatal nutrition","gestational diabetes","feasibility","usability","technology acceptance","mixed methods","2026-03-04",{"date":344,"type":38},{"date":148,"type":22},{"date":378,"type":22},"2027-01-31",{"name":380,"class":45},"Hong Kong Metropolitan University",{"id":382,"slug":383,"hasResults":12,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":387,"eligibilityCriteria":388,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":389,"targetDuration":4,"studyType":23,"phases":391,"briefSummary":392,"conditions":393,"keywords":397,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":408,"locationsCount":65},"100576424","phase-4-a-randomized-placebo-controlled-trial-of-dapagliflozin-dapa-for-cardiovascular-risk-reduction-in-the-postpartum-period-of-hypertensive-pregnancies-hp-100576424","NCT06785116","A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)","A Randomized, Placebo-controlled Trial of DAPAgliflozin for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies","DAPA-HP","Inclusion Criteria:\n\n* Admitted for delivery at the University of Michigan (UM) Labor and Delivery (L\\&D) unit or enrolled in the UM postpartum blood pressure monitoring program following a delivery at the UM L\\&D unit\n* Determined to be at least 23 and 0\u002F7 weeks of gestation based on a clinically acceptable dating method (can be a single or multifetal gestation with or without the presence of fetal anomalies) at the time of delivery\n* Consents to participation and must understand\u002Fread\u002Fspeak English with the ability to understand and willingness to sign a written informed consent in English\n* Diagnosed with a hypertensive pregnancy by either of the following criteria:\n\n  * Taking an antihypertensive medication for the diagnosis of chronic or essential hypertension at the time of admission\n  * Hypertension, chronic hypertension, or essential hypertension must be present in the prospective participant's medical record\n  * Antihypertensive\" can be any medication taken for the purpose of blood pressure control per the medical record\n  * A documented hypertensive disorder of pregnancy (gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, superimposed preeclampsia, or eclampsia) prior to delivery\n* Eligible participants must report a planned contraceptive method as part of the consent process, to be noted on their consent document.\n* Has two or more blood pressures ≥160\u002F110 Millimeters of mercury (mmHg) at least 60 minutes apart\n\n  * If an admitted patient does not meet this blood pressure criterion but is otherwise eligible, participants can consent to have a BNP drawn within 12 hours of delivery as an alternative measure of cardiovascular risk (if the brain natriuretic peptide (BNP) is ≥100 Picograms per milliliter (pg\u002Fml), participants are eligible to participate)\n\nExclusion Criteria:\n\n* Non-English speaking\n* Ongoing pregnancy\n* Stated desire to become pregnant within 8 months post-delivery\n* Intention to breastfeed after enrollment\n* BNP ≥1000 pg\u002Fml within 12 hours of delivery, clinical team to be notified of result\n* Comorbidities that may affect cardiovascular risk assessment (per protocol)\n* Contraindication to dapagliflozin (per protocol)",{"count":390,"type":22},200,[103],"This trial is a pilot-scale, single institution randomized, placebo-controlled trial to assess the feasibility, acceptability, and efficacy of administering dapagliflozin for cardiovascular risk reduction in the postpartum period. The target population is patients at high risk of adverse cardiovascular outcomes within five years post-delivery.\n\nEligible participants will be randomized to receive either: 1) dapagliflozin (10mg daily) for six months (DAPA group) or 2) an orally administered, daily placebo (Control group).\n\nThe study hypothesizes:\n\nThe dapagliflozin group will have higher cardiovascular risk reduction scores than the Control Group.",[109,394,29,395,396],"Hypertension in Pregnancy","Superimposed Pre-Eclampsia","Cardiovascular Complication",[398,399,400,401,402],"Medication","Placebo","Postpartum period","Cardiovascular risk reduction","Echocardiogram","2026-03-01",{"date":374,"type":38},{"date":406,"type":38},"2025-03-02",{"date":63,"type":22},{"name":409,"class":45},"University of Michigan",{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":216,"enrollmentInfo":417,"targetDuration":4,"studyType":23,"phases":419,"briefSummary":420,"conditions":421,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":430,"locationsCount":65},"100547454","phase-3-apple-aspirin-to-prevent-pregnancy-loss-and-preeclampsia-100547454","NCT06408181","APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia","APPLE","Inclusion Criteria\n\n1. Provision of signed and dated informed consent form.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. Ability to take oral medication and be willing to adhere to the prescribed aspirin regimen.\n4. Patients with a gestation less than or equal to 6 weeks, 6 days (as determined by patient record of LMP or ART date).\n5. Patients between 18-45-year old who have one or more risk factors for preeclampsia and\u002For pregnancy loss, including:\n\n   1. preeclampsia in a previous pregnancy,\n   2. gestational diabetes in a previous pregnancy,\n   3. any documentation of fetal growth restriction or low birth weight in a prior pregnancy,\n   4. preterm birth in a previous pregnancy,\n   5. known multifetal gestation at enrollment,\n   6. chronic hypertension,\n   7. pregestational diabetes,\n   8. kidney disease,\n   9. systemic lupus erythematosus,\n   10. nulliparity,\n   11. pre-pregnancy body mass index \\>30,\n   12. family history of preeclampsia (i.e., mother or sister),\n   13. Black persons (due to social, not biological reasons),\n   14. Maternal age 35 years or older,\n   15. lower income (will be determined by qualification of public health insurance),\n   16. conceived with fertility treatment (including in vitro fertilization, ovulation induction, or intrauterine insemination),\n   17. history of one or more prior pregnancy losses \\\u003C20 weeks gestation,\n   18. history of stillbirth in a prior pregnancy,\n   19. An interval of greater than 10 years since the last pregnancy.\n\nExclusion Criteria\n\n1. Known allergies to aspirin or non-steroidal anti-inflammatory agents (NSAID);\n2. Clinical indication for anticoagulant therapy, including prior or current thrombosis, antiphospholipid syndrome, or known major thrombophilia;\n3. Clinical indication for chronic use of NSAIDS during pregnancy;\n4. Medical contraindication to aspirin therapy, including untreated uncontrolled asthma, untreated symptomatic nasal polyps, bleeding disorders, or history of gastrointestinal ulcer.\n5. Patients with pelvic pain or bleeding who require urgent care (i.e., active vaginal bleeding greater than or equal to expected menses, open cervical os suggesting active miscarriage or severe pain requiring evaluation for ectopic pregnancy)",{"count":418,"type":22},1150,[25],"The goal of this clinical trial is to investigate the effects of early initiation of double low-dose aspirin in pregnant women. The main questions it aims to answer are:\n\nDoes this dose and timing of aspirin reduce the risk of pre-eclampsia compared to standard recommendations? Does this dose and timing of aspirin reduce the risk of pregnancy loss compared to standard recommendations? Participants will begin taking at no later than 6 weeks 6 days gestational age, either 162mg of aspirin through delivery or placebo until 12 weeks and then 81mg of aspirin through delivery.",[29,422],"Pregnancy Loss","2026-01-16",{"date":425,"type":38},"2026-01-20",{"date":427,"type":38},"2024-06-12",{"date":429,"type":22},"2029-06",{"name":431,"class":45},"University of Pennsylvania",{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":4,"eligibilityCriteria":438,"healthyVolunteers":134,"sex":18,"minAge":19,"maxAge":272,"enrollmentInfo":439,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":65},"100347632","mechanisms-of-pregnancy-vascular-adaptations-100347632","NCT03806283","Mechanisms of Pregnancy Vascular Adaptations","Angiotensin 2 Receptor (AT2R) Expression\u002FActivation in Endothelial Cells in Preeclampsia","Inclusion Criteria:\n\n* Female\n* Ages 18 to 40 years old\n* Singleton gestation between 28 weeks, 0 days and 41 weeks, 0 days gestational age at the time of consent\n* Undergoing caesarean section, either planned or otherwise with or without trial of labor\n\nExclusion Criteria:\n\n* Treatment of severe hypertension by antihypertensive or use of magnesium sulfate after the patient is hospitalized for the diagnosis of preeclampsia.\n* Any major fetal structural anomalies or aneuploidies\n* Undergoing cesarean section for placental abruption or bleeding complications.\n* Singleton gestation not within 36 weeks, 0 days and 41 weeks, 0 days gestational age at the time of enrollment (delivery)",{"count":440,"type":22},166,"The investigators will collect omental tissue (research surgical excision) and placental tissue (standard of care clinical delivery) from both preeclamptic and non-preeclamptic women during their c-section and use these samples to study the blood vessels, specifically the expression\u002Factivation of the AT2R.",[29,113],"2026-01-15",{"date":425,"type":38},{"date":446,"type":38},"2018-11-20",{"date":448,"type":22},"2027-04",{"name":450,"class":45},"University of Wisconsin, Madison",{"id":452,"slug":453,"hasResults":12,"nctId":454,"briefTitle":455,"officialTitle":456,"acronym":4,"eligibilityCriteria":457,"healthyVolunteers":134,"sex":18,"minAge":19,"maxAge":99,"enrollmentInfo":458,"targetDuration":4,"studyType":23,"phases":460,"briefSummary":462,"conditions":463,"keywords":464,"overallStatus":255,"whyStopped":4,"lastUpdateSubmitDate":466,"lastUpdatePostDateStruct":467,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":4},"100618102","phase-1-pharmacokinetic-study-to-evaluate-safety-and-tolerability-of-eg-101-in-healthy-female-volunteers-as-a-safety-lead-in-for-dosing-in-pregnant-women-with-severe-pre-eclampsia-100618102","NCT07327255","Pharmacokinetic Study to Evaluate Safety and Tolerability of EG-101 in Healthy Female Volunteers as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia","A Phase I, Randomized, Cross-over, Single-Center, Single Dose Fasted Study of EG-101 IV Injection (EG-ZNMP-01) in Healthy Volunteers to Serve as a Safety Lead-In for Dosing in Pregnant Women With Severe Pre-eclampsia","Key Inclusion Criteria:\n\n1. Healthy adult female volunteers, 18 to 55 years of age, inclusive, at first Check-In Visit\n2. Body mass index (BMI) ≥18.5 to ≤32 kg\u002Fm2 at Screening (calculated as a function of measured height and weight according to the formula, BMI = kg \u002F m2 where m2 is height in meters squared.)\n3. All female subjects must be nonpregnant, nonlactating and either postmenopausal, surgically sterile, or using contraceptive regimens more than 3 months. All females must have a negative serum pregnancy test at Screening and Check-in Visit. Effective methods of contraception include a dual method of contraception: condom with spermicide in conjunction with use of an intrauterine device (IUD), condom with spermicide in conjunction with use of a diaphragm, condom with birth control patch or vaginal ring, or condom with oral, injectable, or implanted contraceptive. Surgical sterility is documented through documented: hysterectomy, partial hysterectomy, bilateral oophorectomy, or bilateral tubal ligation at least 6 months prior to Screening. Postmenopausal sterility is documented by absence of menses for at least 12 months prior to Screening plus serum FSH ≥40 mIU\u002FmL and estradiol \\\u003C30 pg\u002FmL at screening\n4. Male subjects, are not enrolled into this study\n5. Medically healthy on the basis of medical history, and physical examination (including but not limited to an evaluation of the cardiovascular, gastrointestinal, respiratory, and central nervous systems), as determined by the Investigator at Screening and each Check-In Visit\n\nKey Exclusion Criteria:\n\n1. Females who are pregnant, lactating, or likely to become pregnant during the study\n2. History and\u002For recent evidence within 6 months prior to Screening of alcohol or drug\u002Fsubstance abuse disorder\n3. Subjects with a history of hypersensitivity to Zanamivir or any component of study medication\n4. History of clinically significant allergies including drug allergies or allergic bronchial asthma or related bronchospastic conditions\n5. Subjects who have history of unexplained syncope or fainting or a condition that predisposes them to syncope, such as hypotension, orthostatic hypotension, bradycardia or dehydration",{"count":459,"type":22},24,[461],"PHASE1","Preeclampsia is one of the leading causes of maternal and fetal death. It is a syndrome of pregnant women and is usually characterized by new onset of hypertension and proteinuria after 20 weeks of gestation. This disease is a multisystem disorder affects most maternal organs, predominantly the vascular, renal, hepatic, cerebral and coagulation systems. While hypertension is almost always a symptom of this disease, preeclampsia is not the same as essential hypertension.\n\nThis is a single-center, randomized, open-label, 4 period, 3-way crossover, single dose fasted study to evaluate the safety, tolerability and pharmacokinetics of four ascending doses of the EG-101 IV injection in healthy volunteers.\n\nTwenty-four subjects in total, with eight subjects randomly assigned to one of three different sequences for variation of doses under fasted conditions. Dosing duration is approximately 4 weeks and followed by the follow-up for each subject.",[141],[465],"Phase 1 Study","2026-01-08",{"date":468,"type":38},"2026-01-12",{"date":470,"type":22},"2026-06",{"date":472,"type":22},"2027-03",{"name":474,"class":156},"Evergreen Therapeutics, Inc.",{"id":476,"slug":477,"hasResults":12,"nctId":478,"briefTitle":479,"officialTitle":480,"acronym":481,"eligibilityCriteria":482,"healthyVolunteers":134,"sex":18,"minAge":19,"maxAge":216,"enrollmentInfo":483,"targetDuration":4,"studyType":23,"phases":485,"briefSummary":486,"conditions":487,"keywords":489,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":497,"completionDateStruct":499,"leadSponsor":501,"locationsCount":65},"100611782","fetal-fornix-and-hippocampus-in-pregnant-women-with-early-onset-preeclampsia-100611782","NCT07245056","Fetal Fornix and Hippocampus in Pregnant Women With Early-Onset Preeclampsia","Evaluation of the Fetal Fornix and Hippocampus in Pregnant Women With Early-Onset Preeclampsia","FHC-EOPE","Inclusion Criteria:\n\n* Women aged 18-45 years\n* Gestational age between 20 and 34 weeks\n* Diagnosis of early-onset preeclampsia (EOPE)\n* Singleton pregnancy\n\nExclusion Criteria:\n\n* Multiple pregnancies\n* Presence of chronic or significant comorbid conditions other than maternal early-onset preeclampsia, including: Chronic, mental, or physical illnesses, severe renal, hepatic, or gastrointestinal acute or chronic inflammatory diseases, hyperthyroidism or hypothyroidism, chronic hypertension, type 1 or type 2 diabetes mellitus, history of polycystic ovary syndrome (PCOS), history of malignancy\n* Fetal congenital or chromosomal anomalies\n* Chronic medication use\n* Tobacco or alcohol use during pregnancy\n* Maternal late-onset preeclampsia (≥34 weeks gestation)",{"count":484,"type":22},84,[76],"Since early-onset preeclampsia (EOPE) is commonly associated with inadequate placentation, placental insufficiency, chronic fetal hypoxia, oxidative stress, and heightened inflammation, these pathological processes may adversely affect hippocampal neuronal development and maturation of axonal pathways such as the fornix. These mechanisms support our hypothesis that fetal fornix and hippocampus dimensions may be reduced in pregnancies complicated by EOPE, forming the scientific basis of our study.\n\nPrevious research has suggested a potential link between preeclampsia (PE) and altered neurocognitive development. However, no studies to date have specifically evaluated the relationship between EOPE and fetal fornix or hippocampus dimensions. Therefore, the objective of our study is to assess fetal fornix and hippocampus measurements in pregnant women with early-onset preeclampsia compared with healthy controls.",[29,488],"Hippocampus",[490,491,492,493],"fetal brain","fornix","hippocampus","early-onset preeclampsia","2025-12-21",{"date":496,"type":38},"2025-12-23",{"date":498,"type":38},"2025-12-01",{"date":500,"type":22},"2026-08-01",{"name":502,"class":503},"Ankara Etlik City Hospital","OTHER_GOV",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":18,"minAge":511,"maxAge":216,"enrollmentInfo":512,"targetDuration":4,"studyType":23,"phases":514,"briefSummary":515,"conditions":516,"keywords":518,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":65},"100615145","phase-4-vitamin-d-for-preventing-recurrent-preeclampsia-in-pregnant-women-100615145","NCT07288801","Vitamin D for Preventing Recurrent Preeclampsia in Pregnant Women","Role of Vitamin D in Prevention of Preeclampsia Recurrence in Pregnant Women With Previous History of Preeclampsia: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Gestational age ≥ 20-weeks (on LMP method) ' - Past medical history of pre-eclampsia\n\nExclusion Criteria:\n\n* Pre-existing hypertension, cardiac diseases, renal disease, thyrotoxicosis (on history and medical record)\n* Women presenting with intra-uterine death of the fetus.","20 Years",{"count":513,"type":22},146,[103],"The goal of this clinical trial is to find out whether giving vitamin D to pregnant women who had pre-eclampsia in a previous pregnancy helps prevent the condition from coming back. The main question it aims to answer is:\n\nDoes vitamin D supplementation reduce the chance of pre-eclampsia recurring in pregnant women with a history of pre-eclampsia?\n\nTo answer this question, pregnant women attending the antenatal clinic at the Department of Obstetrics and Gynaecology, Nishtar Hospital Multan will be invited to join the study.\n\nParticipants will be randomly assigned to two equal groups:\n\n* Vitamin D group: will take 4,000 IU of oral vitamin D until 36 weeks of gestation.\n* Placebo group: will receive a pill identical in appearance, taste, and consistency but without vitamin D.\n\nWhile on the study medication, each woman will visit the clinic every two weeks. At each visit, her blood pressure will be measured, and if it is 140\u002F90 mmHg or higher, a urine test will check for protein to identify pre-eclampsia as per hospital protocol. Any diagnosis of pre-eclampsia will lead to standard care, and the outcome will be recorded.\n\nAt the end, researchers will compare how many women in each group developed recurrent pre-eclampsia.\n\nThis study will help answer whether vitamin D supplementation can safely reduce the risk of pre-eclampsia returning in women with a prior history - a question important for improving pregnancy outcomes and maternal health.",[141,279,517],"Vitamin D",[146,145,519,517],"recurrence","2025-12-04",{"date":522,"type":38},"2025-12-17",{"date":524,"type":38},"2025-08-09",{"date":526,"type":22},"2026-02-08",{"name":528,"class":45},"Nishtar Medical University",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":12,"sex":18,"minAge":536,"maxAge":272,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":539,"briefSummary":540,"conditions":541,"keywords":545,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":553,"completionDateStruct":555,"leadSponsor":557,"locationsCount":65},"100579237","phase-1-autologous-decidual-like-natural-killer-cells-therapy-for-infertility-or-adverse-pregnancy-history-100579237","NCT06821685","Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History","Clinical Study of Autologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History Caused by Abnormal Uterine Natural Killer Cells","Inclusion Criteria:\n\n* abnormal uterine NK cell function;\n* have one of the following medical history: unexplained recurrent spontaneous abortions (≥2 spontaneous abortions, including biochemical pregnancy), repeated implantation failure (failure of implantation of good-quality embryos in at least two IVF cycles), unexplained infertility, early-onset severe gestational hypertension or early-onset fetal growth restriction;\n* have clear fertility desires;\n* normal ovarian function or with frozen embryos;\n* edometrium thickness measured by vaginal ultrasound before ovulation or at mid-luteal phase \\>= 7mm;\n* 18kg\u002Fm\\^2 \\\u003C Body mass index \\\u003C 30kg\u002Fm\\^2;\n\nExclusion Criteria:\n\n* using progesterone receptor modulator;\n* chromosomal karyotype abnormalities in one spouse;\n* severe endometriosis, uterine fibroids affecting the shape of the uterine cavity or the size of the whole uterus more than 2 and a half months of pregnancy, uterine malformation, uterine adhesion or thin endometrium;\n* uncontrolled autoimmune diseases;\n* abnormal blood coagulation function, abnormal liver and kidney function, or other uncontrolled basic diseases (hypertension, diabetes, thyroid disease, etc.) that the researcher access which may affect the progress of the study;\n* history of pelvic malignant tumors;\n* currently participating in other clinical studies;\n* allergic to blood products.","22 Years",{"count":538,"type":22},14,[461],"The aim of this study is preliminary exploration of the effectiveness and duration of autologous decidual-like NK cells therapy in improving uterine NK cells dysfunction.",[542,543,544,29],"Abortion, Habitual","Infertility Unexplained","Embryo Implantation",[546,547,548,549],"recurrent pregnancy loss","repeated implantation failure","unexplained infertility","decidual natural killer cells","2025-11-13",{"date":552,"type":38},"2025-11-17",{"date":554,"type":38},"2025-02-13",{"date":556,"type":22},"2027-12",{"name":558,"class":45},"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School",{"id":560,"slug":561,"hasResults":12,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":272,"enrollmentInfo":567,"targetDuration":4,"studyType":23,"phases":569,"briefSummary":570,"conditions":571,"keywords":573,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":582,"lastUpdatePostDateStruct":583,"startDateStruct":585,"completionDateStruct":587,"leadSponsor":589,"locationsCount":591},"100402421","vascular-biomarkers-predictive-of-the-progression-from-hypertensive-disorders-in-pregnancy-to-preeclampsia-in-pregnant-women-100402421","NCT04520048","Vascular Biomarkers Predictive of the Progression From Hypertensive Disorders in Pregnancy to Preeclampsia in Pregnant Women","Exploratory Study. Endothelial Function and Vascular-tropic Biomarkers: Predictive Indicators of the Progression of Hypertensive Disorders in Pregnancy to Pre-eclampsia?","BIOVASC-PreHTA","Inclusion Criteria:\n\n* Patients with a hypertension disorder in pregnancy and\u002For preeclampsia from the 20th amenorrhea week until the 26th ± 2 amenorrhea week.\n* Age between 18 and 40 years old.\n* Having given written consent.\n* Patients affiliated to a social security scheme.\n\nExclusion Criteria:\n\n* Presence of pathologies interfering in a major way with vascular parameters: known multicomplicated diabetes treated before pregnancy, hypercholesterolemia known (or LDL\\>130 mg\u002Fdl), multicomplicated connectivitis, proven cardiovascular disease (ischemic heart disease, stroke, arteriopathy of the lower limbs, heart failure), pre-existing known renal failure (serum creatinine \\>125 µmol\u002FL) and\u002For pre-existing proteinuria ≥ 300 mg\u002F24h).\n* Cardiac arrhythmia.\n* Hepatitis C, HIV infection (assay performed within 6 months prior to diagnosis of pre-eclampsia).\n* Recent history of venous (pulmonary embolism, phlebitis) or arterial (myocardial infarction, unstable angina, stroke, transient ischemic attack), thrombotic event ≤ 3 months.\n* Patient already engaged in a therapeutic protocol.\n* Patients under legal protective measures.\n* Patients receiving State Medical Assistance.",{"count":568,"type":22},110,[76],"Hypertension during pregnancy remains a leading cause of maternal and fetal morbidity and mortality. The frequency (5 to 10% of pregnancies) and potential severity of these diseases, both for the mother and the child, are reasons for standardizing and optimizing medical practices.\n\nThe cause of hypertension during pregnancy is quite complex, as it depends on a number of factors. Among the hypertensive disorders in pregnancy (HDP), the pathophysiology of pre-eclampsia (one of the most studied in terms of severity) remains poorly understood. The evolution of international guidelines in recent years has made it possible to distinguish various HDP, but schematically we distinguish two main entities by the existence of proteinuria from and after the 20th week of amenorrhea and by maternal-fetal complications, more serious in pre-eclampsia than in gestational hypertension.\n\nAcute placental vasculature and blood flow abnormalities were observed during gestational hypertension and preeclampsia, and maybe due to generalized vascular endothelial activation and vasospasm resulting in systemic hypertension and organ hypoperfusion. Endothelial dysfunction (ED) and abnormal expression of several specific blood biomarkers are now well accepted as characteristics of preeclampsia as a leader.\n\nHowever, the progression of any HDP to preeclampsia is possible, but difficult to predict. By way of example, among between 15 and 40 % of gestational hypertension cases progress to preeclampsia, suggesting that it is the same worsening disease.\n\nED could be pre-existing (chronic, white-coat or masked hypertension) but also at the origin of gestational hypertension (unclassified hypertension, transient pregnancy hypertension), and subsequent development of preeclampsia through an imbalance between pro- and anti-angiogenic factors.\n\nAn imbalance of pro-angiogenic and anti-angiogenic proteins can testify to ED, as can adequate levels of endothelial microparticles.\n\nThe main objective of this research is to assess the presence of urinary endothelial microparticles in stable pregnant women with hypertensive disorder of pregnancy as a marker for the occurrence of pre-eclampsia during pregnancy.",[572,109,29],"Hypertension Disorders in Pregnancy",[574,317,141,575,576,577,578,579,580,581],"Hypertension disorders in pregnancy","Urinary endothelial microparticules","Endothelial dysfunction","Angiogenic biomarkers","Soluble Fms-like- tyrosine kinase 1","Placental Growth Factor","Vascular Endothelial Growth Factor","Microcirculation","2025-09-05",{"date":584,"type":38},"2025-09-12",{"date":586,"type":38},"2023-08-11",{"date":588,"type":22},"2026-12",{"name":590,"class":45},"Assistance Publique - Hôpitaux de Paris",3,{"id":593,"slug":594,"hasResults":12,"nctId":595,"briefTitle":596,"officialTitle":597,"acronym":4,"eligibilityCriteria":598,"healthyVolunteers":134,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":23,"phases":600,"briefSummary":601,"conditions":602,"keywords":603,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":65},"100525475","optic-nerve-sheath-measurement-and-angiogenic-factors-in-patients-with-pre-eclampsia-100525475","NCT06122220","Optic Nerve Sheath Measurement and Angiogenic Factors in Patients With Pre-eclampsia.","Optic Nerve Sheath Measurement and Angiogenic Factors for the Diagnosis of Pre-eclampsia","Inclusion Criteria:\n\n* Pregnant women between 24 and 40 weeks of gestation.\n\nExclusion Criteria:\n\n* Multiple gestation\n* Maternal vasculitis\n* Previous cesarean section (3 or more)\n* Brain or eye tumors\n* Neurological conditions\n* Chronic renal disease\n* Purpura\n* Heart disease",{"count":390,"type":22},[76],"Hypertensive disorders of pregnancy (HPT) are an important cause of maternal-feto-neonatal morbidity and mortality, being one of the three leading causes of maternal death in our country and in developing countries. The only cure for THE is termination of pregnancy, which ends up being a decision in which gestational age and maternal risks must be balanced. Angiogenic factors have come to occupy an indispensable place in the arsenal of tools that can be used to separate the patient with a high likelihood of complications from those in whom prolongation of pregnancy could represent an important neonatal benefit. Refining the diagnostic capability of this test would further improve maternal-fetal outcomes and the use of optic nerve sheath diameter (ONSD) measurement could make the difference.\n\nThe purpose of the present study is to correlate the measurement of ONSD with serum angiogenic factor (AF) values in patients with pre-eclampsia and to determine its predictive ability for adverse perinatal outcomes.",[29],[604,605,141],"Angiogenic factors","Optic nerve sheath diameter","2025-08-23",{"date":608,"type":38},"2025-08-26",{"date":610,"type":38},"2025-08-15",{"date":612,"type":22},"2026-01-30",{"name":614,"class":45},"Saint Thomas Hospital, Panama",{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":620,"acronym":4,"eligibilityCriteria":621,"healthyVolunteers":134,"sex":135,"minAge":4,"maxAge":4,"enrollmentInfo":622,"targetDuration":624,"studyType":56,"phases":4,"briefSummary":625,"conditions":626,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":630,"lastUpdatePostDateStruct":631,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":65},"100524929","peppi-study-identification-of-women-at-risk-for-placental-dysfunction-100524929","NCT06115122","PEPPI Study: Identification of Women at Risk for Placental Dysfunction","PEPPI Study: Identification of Women at Risk for Placental Dysfunction During the First and Third Trimesters of Pregnancy","Mothers\n\nInclusion Criteria for PEPPI-study\n\n* Pregnant (first trimester)\n* Understands Finnish\n* ≥18 years\n* Signed informed consent\n\nExclusion Criteria\n\n* Multiple pregnancy\n* Miscarriage\u002Ftermination of the index pregnancy\n* No first trimester blood sampling\n\nInclusion Criteria for FERPPI-study\n\n* Participates in PEPPI-study (criteria above)\n* Blood samples at first and third trimester of pregnancy\n* Permits blood sampling from the umbilical cord when the baby is born\n\nExclusion Criteria\n\n* No first or third trimester blood sampling\n* No umbilical cord blood sample after baby is born\n\nFathers\n\nInclusion Criteria\n\n* Biological father to the child born for the mother who participated in PEPPI study\n* ≥18 years\n* Signed informed consent\n\nExclusion Criteria\n\n• Does not understand Finnish\n\nChildren\n\nInclusion Criteria for PEPPI-study\n\n* Born to mother who participated in PEPPI study\n* Signed informed consent from parent(s)\n\nExclusion Criteria\n\n• No consent from parent(s)\n\nInclusion Criteria for PEPPI-offspring study • Mother in risk-, control-, or PCOS group during PEPPI-study with ultrasound information at gestational weeks 30-32 or a mother who developed pre-eclampsia during the pregnancy regardless of their study group during PEPPI-study\n\nExclusion Criteria\n\n• Mother\u002Ffather declines participation\n\nInclusion Criteria for FERPPI-study\n\n* Signed informed consent from parent(s)\n* Mother has blood samples taken at first and third trimester (iron status)\n* Child has blood samples taken at birth and at 3 months of age\n\nExclusion Criteria\n\n* No consent from parent(s)\n* No blood samples from mother\n* No blood samples from child",{"count":623,"type":22},3000,"15 Years","The main purpose of this study is to evaluate Fetal Medicine Foundation's pre-eclampsia risk calculator using maternal characteristics, first trimester serum placental growth factor (PlGF) and mean arterial pressure (MAP) in a Finnish general population.\n\nCondition or disease: pre-eclampsia, intrauterine growth restriction, polycystic ovary syndrome",[29,30,627,628,110,106,629],"Polycystic Ovary Syndrome","Iron-deficiency","Proteinuria in Pregnancy","2025-07-31",{"date":632,"type":38},"2025-08-05",{"date":634,"type":38},"2022-02-15",{"date":636,"type":22},"2041-12-31",{"name":638,"class":45},"Oulu University Hospital",{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":645,"eligibilityCriteria":646,"healthyVolunteers":134,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":647,"targetDuration":4,"studyType":23,"phases":649,"briefSummary":650,"conditions":651,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":652,"lastUpdatePostDateStruct":653,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":659,"locationsCount":65},"100524455","screening-for-preeclampsia-in-norway-with-aspirin-discontinuation-at-24-28-weeks-100524455","NCT06108947","Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks","Implementing Screening for Preeclampsia in Norway With Aspirin Discontinuation at 24-28 Weeks - a Randomized Controlled Trial","PEScreenNor","Inclusion Criteria\n\n* 18 years or older\n* singleton live fetus with gestational age between 24 and 28 weeks\n* woman with high risk of preterm preeclampsia (\\>1\u002F100) in the first trimester screening\n* aspirin treatment with a dose 150 mg per day initiated at 16+6 weeks of gestation or less until randomization with adherence of at least 50%\n* low SFlt-1\u002FPlGF ratio (Kryptor technology with cut-off 66) measured at 24-28 weeks\n\nExclusion Criteria\n\n* not speaking Norwegian or English language\n* fetal anomalies diagnosed with ultrasound\n* informed consent for participation in the trial",{"count":648,"type":22},300,[76],"Study population Around 3500 pregnant women attending a routine ultrasound scan at 11-14 weeks at St. Olavs hospital, Trondheim, Norway.\n\nStudy period Dec 2023 - Jul 2025\n\nScreening Patient history, blood pressure, uterine artery mean PI and PlGF will be plotted in the FMF algorithm for screening for preeclampsia in the first trimester. Standardized blood pressure will be measured by trained personnel. Ultrasound scans will be performed by FMF certified doctors and midwives working at the Center for Fetal Medicine in Trondheim. Placenta growth factor (PLGF) will be analyzed with Kryptor technology at Center for Laboratory Medicine, St. Olavs hospital.\n\nProphylaxis Women with high risk for preterm preeclampsia (risk \\> 1:100) will be offered aspirin prophylaxis 150 mg x 1 from 11-14 weeks to 36 weeks. Women will be offered to participate in a randomized controlled trial (RCT).\n\nStudy design and participants in the RCT A single center, open label, randomized, noninferiority trial conducted at St. Olavs hospital, Trondheim Norway from Dec 2023 to Jul 2025. The investigators will include around 300 women 18 years or older with a singleton live fetus, gestational age between 24 and 28 weeks, high risk of preterm preeclampsia (\\>1\u002F100) in the first trimester screening, aspirin treatment with a dose 150 mg per day initiated at 16+6 weeks of gestation or less until randomization with a adherence of at least 50% and low SFlt-1\u002FPlGF ratio (Kryptor technology with cut-off 66).\n\nRandomization and masking Between 24 and 28 weeks of gestation, participants will be randomly designed, with a computer-based system in a 1:1 ratio, to continue aspirin (control group) or discontinue aspirin (intervention group). This is an open-label study without masking of patients or providers.\n\nFollow-up Both groups will have visits every 4 weeks between randomization and 36 weeks, and standard antenatal care after 37 weeks until delivery. Treatment adherence will be assessed by patient self-report and tablet count, and fetal growth and Doppler will be assessed at the scheduled visits between randomization and 36 weeks (at 24, 28, 32 and 36 weeks), and according to clinical judgement by obstetricians at the outpatient clinic of the hospital. Women will have a telephone\u002Fvideo link follow-up 1-2 months after birth",[29],"2025-06-04",{"date":654,"type":38},"2025-06-05",{"date":656,"type":38},"2024-01-01",{"date":658,"type":22},"2027-06",{"name":660,"class":45},"St. Olavs Hospital",{"id":662,"slug":663,"hasResults":12,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":667,"eligibilityCriteria":668,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":669,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":671,"conditions":672,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":675,"lastUpdatePostDateStruct":676,"startDateStruct":678,"completionDateStruct":680,"leadSponsor":681,"locationsCount":65},"100422651","early-prediction-of-preeclampsia-using-arterial-stiffness-in-high-risk-pregnancies-100422651","NCT04783597","Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies","Early Prediction of Preeclampsia Using arteriaL Stiffness in High-risk prEgnancies; a Multinational Study (PULSE)","PULSE","Inclusion Criteria:\n\n* Singleton pregnancy\n* Presence of at least 1 high-risk factor or 2 moderate-risk factors for pre-eclampsia\n\nExclusion Criteria:\n\n* \\>14 weeks gestation\n* Multiple pregnancy\n* History of heart disease, stroke, or peripheral arterial disease\n* Infectious diseases\u002Fconditions, such as Hepatitis B\u002FC, HIV, and COVID19",{"count":670,"type":22},2400,"Despite advances in obstetric care, preeclampsia (PE) remains the leading cause of maternal death and disability in both developed and developing countries, contributing to over 70,000 maternal and 500,000 fetal deaths annually worldwide. PULSE was designed using a preventative medicine approach, focusing on improving early detection of PE as opposed to managing symptoms after onset. The study aims to uncover the earliest possible signs of PE using a combination of novel clinical tools and established diagnostic techniques to better identify, track, and manage high risk pregnant women. Specifically, PULSE will be examining the incorporation of a non-invasive test for the measurement of arterial stiffness, which has been shown to be predictive of hypertensive disorders. This test, in combination with a wide range of blood biomarkers, detailed ultrasound imaging, and a comprehensive battery of physical and mental health questionnaires, represents the largest, most comprehensive preventative PE study to date. The results of this work has the potential to revolutionize the way PE and other hypertensive disorders of pregnancy are managed and treated and can serve to inform the design of future preventative clinical research studies.",[673,674,29],"High Risk Pregnancy","Arterial Stiffness","2025-04-15",{"date":677,"type":38},"2025-04-18",{"date":679,"type":38},"2021-07-12",{"date":262,"type":22},{"name":682,"class":45},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre"]